In Vitro Activities of β-Lactam-β-Lactamase Inhibitor Antimicrobial Agents against Cystic Fibrosis Respiratory Pathogens

被引：29

作者：

Caverly, Lindsay J. ^{[1
]}

Spilker, Theodore ^{[1
]}

Kalikin, Linda M. ^{[1
]}

Stillwell, Terri ^{[1
]}

Young, Carol ^{[2
]}

Huang, David B. ^{[3
,4
]}

LiPuma, John J. ^{[1
]}

机构：

[1] Univ Michigan, Sch Med, Dept Pediat, Ann Arbor, MI 48109 USA

[2] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA

[3] Motif BioSci, Princeton, NJ USA

[4] Rutgers New Jersey Med Sch, Trenton, NJ USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2020年 / 64卷 / 01期

基金：

美国国家卫生研究院;

关键词：

cystic fibrosis; respiratory tract infection; ceftazidime-avibactam; ceftolozane-tazobactam; meropenem-vaborbactam; IDENTIFICATION; EPIDEMIOLOGY; GENE;

D O I：

10.1128/AAC.01595-19

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

We tested the in vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam, piperacillin-tazobactam, and 11 other antimicrobial agents against 420 Burkholderia, Achromobacter, Stenotrophomonas, and Pandoraea strains, 89% of which were cultured from respiratory specimens from persons with cystic fibrosis. Among the beta-lactam-beta-lactamase inhibitor agents, meropenem-vaborbactam had the greatest activity against Burkholderia and Achromobacter, including multidrug-resistant and extensively-drug-resistant strains. None of the newer beta-lactam-beta-lactamase combination drugs showed increased activity compared to that of the older agents against Stenotrophomonas maltophilia or Pandoraea spp.

引用

页数：4

共 14 条

[11] Changing Epidemiology of the Respiratory Bacteriology of Patients With Cystic Fibrosis [J].

Salsgiver, Elizabeth L. ;

Fink, Aliza K. ;

Knapp, Emily A. ;

LiPuma, John J. ;

Olivier, Kenneth N. ;

Marshall, Bruce C. ;

Saiman, Lisa .

CHEST, 2016, 149 (02) :390-400

[12] Identification and distribution of Achromobacter species in cystic fibrosis [J].

Spilker, Theodore ;

Vandamme, Peter ;

LiPuma, John J. .

JOURNAL OF CYSTIC FIBROSIS, 2013, 12 (03) :298-301

[13] Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections [J].

Waters, Valerie J. ;

Kidd, Timothy J. ;

Canton, Rafael ;

Ekkelenkamp, Miquel B. ;

Johansen, Helle Krogh ;

LiPuma, John J. ;

Bell, Scott C. ;

Elborn, J. Stuart ;

Flume, Patrick A. ;

VanDevanter, Donald R. ;

Gilligan, Peter ;

Bullington, Wendy ;

Burgel, Pierre-Regis ;

Byrnes, Catherine ;

Drevinek, Pavel ;

Holmes, Alison ;

Kahl, Barbara ;

Maples, Holly ;

Martiniano, Stacey ;

McColley, Susanna ;

Morris, Andrew ;

Muhlebach, Marianne ;

Parkins, Michael ;

Ratjen, Felix ;

Roberts, Jason ;

Saiman, Lisa ;

Shah, Anand ;

Smyth, Alan ;

Somayaji, Ranjani ;

Taccetti, Giovanni ;

Tunney, Michael ;

Winthrop, Kevin ;

Zemanick, Edith .

CLINICAL INFECTIOUS DISEASES, 2019, 69 (10) :1812-1816

[14] Identification and detection of Stenotrophomonas maltophilia by rRNA-directed PCR [J].

Whitby, PW ;

Carter, KB ;

Burns, JL ;

Royall, JA ;

LiPuma, JJ ;

Stull, TL .

JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (12) :4305-4309

← 1 2 →